Wutah dodolan YoY sajrone rolas wulan kepungkur: Metsera Therapeutics (MTSR)

Metsera Inc (MTSR) relies on an asset-light model, outsourcing drug production to external CMOs. Year-over-year sales dynamics based on TTM methodology on GURU.Markets reflect the current value of 0.00, highlighting a dependence on expensive cold-chain logistics. The R&D stage and venture financing drive the company's success, which now depends entirely on FDA regulatory approval.

This indicator measures revenue dynamics over the trailing twelve months relative to the same period last year, reflecting the pace of business scaling. For Metsera Inc (MTSR), this metric confirms the effectiveness of its expansion into the obesity drug segment, which is seeing colossal global demand. By analyzing the year-over-year percentage change in sales volume for the LTM, an investor assesses the speed of market share capture. Steady growth in this figure indicates fundamental stability and high capitalization potential for the company.